Livzon gets drug registration acceptance for reflux treatment

Livzon Pharmaceutical Group Inc announced that its application for domestic production and drug registration of JP-1366 tablets has been accepted by the National Medical Products Administration. The 20mg tablets treat reflux esophagitis.

JP-1366 is an innovative potassium-competitive acid blocker. Phase III clinical trials completed in June 2025 demonstrated non-inferiority to Nexium in esophageal mucosal healing.

Cumulative R&D investment in JP-1366 tablets totals approximately 185.2m yuan. The domestic P-CAB market in China reached approximately 1.25bn yuan in 2024, up 81.22% year-on-year. Q1 2025 sales were 394.3m yuan, up 81.63% year-on-year.